Position Statements & Consultation Documents

Position Statements & Consultation Documents

Here are the presentations from the VicTAG Education Webinar held after the Annual General Meeting 2023:

Check Again: Improving antibiotic treatment options for patients with penicillin allergy - Misha Devchand, Safer Care Victoria

Improving childhood asthma management inner west pilot project a- Rachel Vorlander, Safer Care Victoria

VicTAG framework for the implementation and integration of automated dispensing cabinets - Viviane Khalil, Monash Health

VicTAG framework for the management of Schedule 9, Schedule 8 and Schedule 4D medications - Cynthia Donarelli, Northern Health

Medication safety assessment of pharmaceutical products - Rowena Treseder, Alfred Health

VicTAG medication safety alerts and 2023 highlights - Connie Yin, VicTAG


Thank you to all our presenters at the event.

The VicTAG QUM Committee Terms of Reference is available here:

VicTAG QUM Committee Terms of Reference 2024

The Medicines and Poisons Regulation opened a public consultation in relation to the proposed amendment to include pregabalin, gabapentin and tramadol in SafeScript. 

The  Regulatory Impact Statement (RIS) in relation to the proposed Drugs, Poisons and Controlled Substances Amendment Regulations 2023 (proposed Regulations) has been prepared in accordance with section 11 of the Subordinate Legislation Act 1994. The RIS presents the cost to prescribers and pharmacists implementing the proposed Regulations and the expected health, social and financial benefits.

The RIS draws on the findings of the Austin Health updated literature review with regards to the evidence of harms caused by pregabalin, gabapentin and tramadol. You can find the full report here -


Links below to consultation documents and the response submitted by VicTAG

Regulatory Impact Statement - Schedule 5 & Schedule 6 of the DPCS Regulations 2017

Exposure draft - DPCS Amendment Regulations 2023

VicTAG Response to proposed amendement



You must be a member and be signed in to view this page. Please click here to login if you are already a member.



In November 2019, a workshop on strategies to deal with the lack of development into agents targeting microbial infections was held.  The current business model for drug development does not work with antimicrobials and consequently almost all large pharma are no long involved in drug development in this space.

The meeting was to discuss different options with various players and the slides are available below.